Background: Although the clinical benefit of interleukin-2-receptor antibody (IL-2RAb) induction in reducing the risk of acute rejection in adult kidney transplant recipients is well established, a similar benefit in paediatric recipients remains controversial. The aim of this study is to evaluate the efficacy of IL-2RAb in reducing acute rejection in paediatric and adolescent recipients aged
http://ift.tt/2gR0hWK
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου